Related references
Note: Only part of the references are listed.Inference of CRISPR Edits from Sanger Trace Data
David Conant et al.
CRISPR JOURNAL (2022)
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
Maroun Bou Zerdan et al.
International Journal of Hematologic Oncology (2022)
The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
Edward Z. Song et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity
Andrea Schmidts et al.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy
Gregory M. Chen et al.
CANCER DISCOVERY (2021)
Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma
Ksenia Bezverbnaya et al.
CYTOTHERAPY (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
Tianzhi Wu et al.
INNOVATION (2021)
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
Benjamin Philipson et al.
SCIENCE SIGNALING (2020)
SMAC mimetics as potential cancer therapeutics in myeloid malignancies
Prajwal Boddu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tori N. Yamamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Fcμ receptor as a Costimulatory Molecule for T Cells
Andreas Meryk et al.
CELL REPORTS (2019)
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors
Andreas A. Hombach et al.
MOLECULAR THERAPY (2019)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Patrick A. Baeuerle et al.
NATURE COMMUNICATIONS (2019)
Antagonism of IAPs Enhances CAR T-cell Efficacy
Jessica Michie et al.
CANCER IMMUNOLOGY RESEARCH (2019)
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers
Xiulei Mo et al.
CELL CHEMICAL BIOLOGY (2019)
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Christopher W. Helsen et al.
NATURE COMMUNICATIONS (2018)
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
Yiyang Xu et al.
CELL DISCOVERY (2018)
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
John Matthew R. Pierce et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Marta Chesi et al.
NATURE MEDICINE (2016)
Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling
A. J. Kocab et al.
ONCOGENE (2015)
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Joanne A. Hammill et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
V. Ramakrishnan et al.
LEUKEMIA (2014)
X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy
Petra Obexer et al.
FRONTIERS IN ONCOLOGY (2014)
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Ashley J. Knights et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
IAP inhibitors enhance co-stimulation to promote tumor immunity
Michael Dougan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Two distinct signalling cascades target the NF-κB regulatory factor c-IAP1 for degradation
Rebecca A. Csomos et al.
BIOCHEMICAL JOURNAL (2009)
XIAP discriminates between type I and type II FAS-induced apoptosis
Philipp J. Jost et al.
NATURE (2009)
Memory T cells need CD28 costimulation to remember
Alina C. Boesteanu et al.
SEMINARS IN IMMUNOLOGY (2009)
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer
Brian A. Rabinovich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
IAP antagonists target cIAP1 to induce TNFα- dependent apoptosis
James E. Vince et al.
CELL (2007)
Smac mimetics and TNFα:: A dangerous liaison?
Hao Wu et al.
CELL (2007)
Autocrine TNFα signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis
Sean L. Petersen et al.
CANCER CELL (2007)
Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology
T Brunner et al.
SEMINARS IN IMMUNOLOGY (2003)
XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95-and Bax-induced apoptosis
SB Bratton et al.
CELL DEATH AND DIFFERENTIATION (2002)
CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression
LJ Appleman et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
